Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead Sciences Inc

1 Dividend Stock You'll Be Thankful to Own in 2023

With the market relapsing into a fresh bout of the volatility after estimate-crushing employment numbers, high dividend-yielding and fundamentally sound stock Gilead Sciences (GILD) could help investors secure a steady income stream. Read on….

StockNews.com

3 Must-Have Dividend Stocks for 2023

January’s robust job report is raising concerns about how long the Fed will keep interest rates high. Market experts are now expecting a higher terminal interest rate. As uncertainty clouds over, quality stocks Gilead Sciences (GILD), Valero Energy (VLO), and ARC Document (ARC) that pay stable dividends might be ideal…

StockNews.com

2 Stocks to Help Jump-Start Your Passive Income in 2023

Despite an inflow of positive macro data, the Fed’s hawkish stance is expected to keep the markets under pressure for the near term. With price fluctuations being the new norm, dividend-paying stocks with solid fundamentals, BHP Group (BHP) and Gilead Sciences (GILD), could help jump-start a solid stream of passive…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

These 3 Dividend Stocks Are Worth Investing In

While the better-than-expected GDP growth in the last quarter and declining inflationary pressures are raising optimism, macro uncertainties remain. With interest rate hikes expected to continue, recession possibilities cannot be ruled out. Therefore, fundamentally sound dividend-paying stocks, AbbVie (ABBV), Gilead Sciences (GILD), and Sisecam Resources (SIRE), could be worth investing…

StockNews.com

1 Biotech Stock to Buy in January 2023 and 1 to Sell

Amid rising demand and government investments, the biotech industry is poised to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stock Gilead Sciences (GILD) might be a wise addition to your portfolio this January. However, Stoke Therapeutics (STOK) could be best avoided, given its bleak fundamentals.…

StockNews.com

1 High-Yield Dividend Stock You Can Count on in 2023

With the Federal Reserve committed to bringing inflation down, a pause in interest rate hikes is not expected this year. This is expected to lead to an economic slowdown and keep the stock market volatile. Amid this backdrop, investors could add a high-yield stock, Gilead Sciences (GILD), to stabilize their…

StockNews.com

3 Top-Rated Stocks to Buy for the Long Haul

Amid economic turmoil and recessionary fears, market volatility is anticipated to continue. However, this could be an opportune time for investors to scoop up quality top-rated stocks Gilead Sciences (GILD), Biogen (BIIB), and AudioCodes (AUDC) for the long haul. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Get the Most Bang for Your Buck With These 3 Stocks

With data starting to reveal signs of a slowdown in an economy burdened with inflation and reactive interest rate hikes, loading up on fundamentally strong stocks Gilead Sciences (GILD), Kronos Worldwide (KRO), and Bluegreen Vacations Holding (BVH) at discounted valuations could set investors up for outsized returns. Continue reading….

StockNews.com

2 Nasdaq Stocks to Buy Now and Hold All of 2023

Thanks to easing inflation and indications of lower interest rate hikes by the Federal Reserve, the Nasdaq composite could rebound after its freefall last year. Given this backdrop, fundamentally sound Nasdaq stocks Cisco Systems (CSCO) and Gilead Sciences (GILD) could be ideal buy-and-hold options in 2023. Keep reading….

StockNews.com

2 Biotech Stocks Under $100 to Buy Now

The biotech industry flourished amid the pandemic, and lucrative federal investments are expected to drive further growth in the sector. Moreover, amid evolving variants of Coronavirus, the biotech industry is expected to remain in the limelight. Given the sound prospects of the industry, quality biotech stocks Gilead Sciences (GILD) and…

StockNews.com

These 3 Stocks Pay You to Own Them

Although inflation has been showing signs of easing, it continues to hover way above the Fed’s 2% target. Since the Fed is expected to continue raising interest rates until its target is reached, the stock market is expected to remain volatile. Amid this backdrop, investors could consider investing in quality…

StockNews.com

3 High-Yield Dividend Stocks to Buy in a Sea of Market Volatility

The latest jobs report indicated that the Fed’s aggressive rate hikes have begun to yield results, but they still have a long way to go. With the market likely to be choppy in the near term, investors could invest in high-yield dividend stocks Gilead Sciences (GILD), KT Corp. (KT), and…

StockNews.com

Want Passive Income in a Bear Market? Check out This Biotech Stock

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

StockNews.com

2 Biotech Stocks to Buy Amid a Blazing Hot Run

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Consider Buying These 2 Biotech Stocks Before 2023

The biotech industry is expected to thrive amid the increasing medical requirements and greater investments in research and development. Moreover, investor sentiment toward biotech stocks has dramatically improved in recent months as the recession possibilities are rising. As this sector is known to provide a hedge against market downturns, investors…

StockNews.com

2 COVID-19 Stocks That Are Still Strong Buys

Given that COVID-19 is here to stay for the foreseeable future, investors could still benefit from their investments in companies that saw record-breaking sales during the pandemic’s height because of the effectiveness of their products in fighting the virus. With the potential resurgence of COVID-19 in several countries, Pfizer (PFE)…

StockNews.com

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

StockNews.com

3 Biotech Stocks to Help You Build a Healthy Portfolio

Biotech industry played a vital role amid the pandemic and continues to witness solid demand amid rising medical needs and chronic diseases. Investor sentiment toward biotech stocks is robust. As biotech is considered a defensive sector against market downturns, investors might buy quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB),…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

GILD Stock: Is It Still a Smart Investment Ahead of 2023?

GILD gained prominence during the pandemic, but the company’s COVID-19 drug Veklury registered a decline in sales because of declining COVID-19 cases. However, it beat revenue and earnings estimates in the previous quarter. Will the company be able to record further growth in the coming year? Read more to learn…

StockNews.com

3 Stocks to Buy Now for Less Than a Fancy Dinner Out

Although inflation seems to be slowing, the possibility of the Fed continuing rate hikes has led to recessionary concerns. Given the uncertainties ahead, we advise our investors to invest in fundamentally sound stocks, Coca-Cola (KO), Gilead Sciences (GILD), and PBF Energy (PBF). These stocks are currently trading at a relatively…

StockNews.com

The 3 Best Dividend Stocks to Purchase Right Now

Rising market uncertainties and recessionary fears, anticipated to hit in 2023, have led investors to safeguard their portfolios and ensure a steady flow of income. Against this backdrop, quality dividend stocks Natural Resource Partners (NRP), Spok Holdings (SPOK), and Gilead Sciences (GILD) could be best purchases now. Read on….

StockNews.com

2 Biotech Stocks to Add to Your Portfolio in Q4

Despite lingering macro issues, the biotech industry is expected to witness robust growth. Moreover, amid rising medical needs and chronic diseases, research and development in the biotech sector are expected to expand, contributing to its growth. Therefore, investors might add quality biotech stocks Gilead Sciences (GILD) and Biogen (BIIB) to…

StockNews.com

2 Biotech Stocks to Buy in November and 1 to Sell

The biotech industry strengthened over the pandemic by drug and vaccine development initiatives to combat COVID-19. Moreover, significant government investments should bode well for this industry. Therefore, quality biotech stocks Amgen (AMGN) and Gilead Sciences (GILD) could be ideal buys in November. However, fundamentally weak stock Ginkgo Bioworks (DNA) might…

StockNews.com

2 Dividend Stocks You Shouldn’t Wait Any Longer to Buy

Amid rising market uncertainties, investors are increasingly opting for dividend stocks to safeguard their portfolios and ensure a steady income stream. We believe fundamentally sound stocks Gilead Sciences (GILD) and Flowers Foods (FLO), which have impressive dividend-paying records, are ideal additions to your portfolio now. Keep reading….

StockNews.com

The 4 Best Stocks to Buy This November

Favorable inflation data for October has raised the odds of slower federal rate hikes ahead. The market has been celebrating the inflation report, and experts believe the current rally could sustain for a while. Therefore, investors could buy quality stocks such as Gilead Sciences (GILD), Biogen (BIIB), Hillenbrand (HI), and…

1 2 3 4 5

People

Jerome Powell

2,788 stories

Dipanjan BanchurSince

722 stories

Kritika SarmahHer

714 stories

Mangeet Kaur BounsMangeet

595 stories

Santanu RoyHaving

215 stories

Sristi Suman Jayaswal

90 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.